The tirzepatide 2mg (2.5mg) starting dose: what the evidence says

What the trial evidence tells us about the starting phase

The SURMOUNT-1 study, whose results were published in the New England Journal of Medicine, randomised 2,539 adults with obesity to tirzepatide or placebo over 72 weeks. Participants who reached the 15mg maintenance dose recorded average body-weight reductions of roughly 20–21%. None of that happened at the starter strength. The 2.5mg phase (typically the first four weeks) is a tolerability measure, there to let gastrointestinal side effects settle before the first increase to tirzepatide 5mg, the next strength in the sequence. Nausea, loose stools and indigestion are most common early in treatment or after a dose step; beginning low and moving slowly is specifically designed to reduce how sharp those effects feel.

One thing worth clearing up: some people searching for a "2mg" dose have seen that figure in forum posts or older articles. It does not correspond to any licensed tirzepatide strength in the UK. If you want to understand how the tirzepatide dose schedule is structured, the actual sequence runs 2.5, 5, 7.5, 10, 12.5 and 15mg, six strengths in all, each on its own pre-filled KwikPen. If you've read about a 2mg dose somewhere, it's a misprint or a confusion with another medicine.

For a fuller picture of how the dose ladder is structured, the tirzepatide dosing overview sets out each step and the typical timescales involved.

How the 2.5mg dose sits within the full titration schedule

NICE's appraisal of tirzepatide (TA1026, published December 2024 and updated September 2025) formally recommends the medicine for adults who meet BMI and clinical criteria, and the clinical pathway it describes begins at 2.5mg. The NICE TA1026 recommendations make clear that if a patient does not achieve at least 5% body-weight reduction after six months at the highest tolerated dose, continuing treatment should be reviewed. That framing matters: the starting dose is part of a long arc, not a treatment in itself.

In practice, a prescriber will typically review progress before authorising each upward step. At nume, a named, GPhC-registered Independent Prescriber reads your answers personally before every repeat, the same clinical review happens whether you're on 2.5mg or 12.5mg. There is no automated dose increase. If you're curious about what the next step up looks like in clinical terms, our tirzepatide 5 mg page covers the first increase and what evidence says about it.

The 2.5mg pen contains four weekly doses (one month of treatment) injected subcutaneously into the abdomen, thigh or upper arm, rotating sites each time. Storage is refrigerated at 2–8°C; the Patient Information Leaflet specifies the exact room-temperature window if you need it outside the fridge, and that leaflet is the right place to check rather than any general-purpose article.

Side effects at the starting dose: what to expect and when to act

Most people tolerate the 2.5mg phase better than they expect. The gastrointestinal effects (nausea, constipation, loose stools, burping, reflux) tend to be at their sharpest when a new dose begins, which is exactly why the schedule starts low. For the majority, these effects ease within days to a couple of weeks as the body adjusts.

A small number of people experience more persistent symptoms. Severe, sustained stomach pain that spreads toward the back warrants urgent medical attention: in January 2026, the MHRA issued a Drug Safety Update for GLP-1 receptor agonist medicines specifically highlighting acute pancreatitis as a known, if infrequent, serious side effect. The symptom profile described (severe abdominal pain, sometimes with vomiting) is the threshold at which you should stop the injection and seek help promptly, not wait for your next scheduled review.

Other signs that need prompt attention include symptoms of a severe allergic reaction, significant dehydration from persistent vomiting or diarrhoea, and gallbladder pain. For a broader account of the side-effect picture across all doses, the Mounjaro treatment overview covers them alongside the clinical context. Suspected side effects can also be reported directly through the MHRA Yellow Card scheme, patients can do this themselves, not just clinicians.

Tirzepatide is not licensed for use in people under 18, during pregnancy, or while breastfeeding. Anyone trying to conceive should discuss timing with their prescriber, since the medicine is not recommended in that period either. Women on oral contraceptives starting tirzepatide should add a non-oral method for the first four weeks and for four weeks after each dose increase, as absorption of the pill may be reduced at the start of each new strength.

Getting tirzepatide through a regulated private service

Tirzepatide is a Prescription-Only Medicine. In the UK, the only lawful route to it is a prescription issued by a qualified prescriber following a clinical assessment of your individual circumstances. NHS access to tirzepatide under NICE TA1026 is real but phased, current eligibility thresholds are strict, and GP practice participation is optional, so availability varies by area. Private treatment through a regulated online pharmacy is the practical alternative for people who don't meet the current NHS criteria or prefer not to wait.

If cost is part of your thinking, the Mounjaro cost guide sets out what private treatment realistically involves and what a legitimate quoted price should include. For anyone ready to take the next step, checking your eligibility with our prescribers starts with a free consultation, reviewed the same day by a real clinician, not a decision tree.